Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mediwound Ltd Ord Sh
(NQ:
MDWD
)
17.07
+0.03 (+0.15%)
Streaming Delayed Price
Updated: 10:46 AM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mediwound Ltd Ord Sh
< Previous
1
2
3
4
5
Next >
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
August 15, 2024
Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages
From
MediWound Ltd.
Via
GlobeNewswire
MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024
August 14, 2024
MDWD stock results show that MediWound missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
August 14, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Preview: MediWound's Earnings
March 20, 2024
Via
Benzinga
Recap: MediWound Q3 Earnings
November 21, 2023
Via
Benzinga
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
August 05, 2024
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Second Quarter 2024 Financial Results
August 02, 2024
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
July 29, 2024
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
July 16, 2024
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces $25 Million Strategic Private Placement Financing
July 15, 2024
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment
From
MediWound Ltd.
Via
GlobeNewswire
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 05, 2024
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family
Via
Benzinga
US Stocks Mixed; Jobs Figures Top Estimates For June
July 05, 2024
Via
Benzinga
Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
July 05, 2024
Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after the company announced it received two purchase orders for a total of approximately one million...
Via
Benzinga
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024
May 29, 2024
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
May 29, 2024
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report First Quarter 2024 Financial Results
May 22, 2024
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
April 25, 2024
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
April 17, 2024
Via
Investor Brand Network
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
March 21, 2024
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 21, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
February 12, 2024
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients...
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Participate in Two Upcoming Investor Conferences
February 05, 2024
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
January 09, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
December 28, 2023
Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S.
Via
Benzinga
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
December 28, 2023
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
December 21, 2023
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Scheduled For November 21, 2023
November 21, 2023
Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.11 per share on revenue of $149.42 million.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.